PubMed Health⌕ Search

Biomedical subjects

M Rousset

Publications and source records attributed to M Rousset.

At least 73 records · Page 4Linked to original sources
PubMed1984

Growth-related enzymatic control of glycogen metabolism in cultured human tumor cells.

The activities of glycogen synthase and phosphorylase were measured and compared to the growth-related variations of glycogen accumulation in three cultured human tumor cell lines: HT-29 (colon carcinoma); MeWo (malignant melanoma); and RT-4 (carcinoma of the urinary bladder). A similar pattern of variations in the enzyme activities was found in the three cell lines. The activities of the a + b forms of glycogen phosphorylase increased throughout the culture period. Maximal activity of phosphorylase a coincided with low intracellular concentrations of glycogen during the period of exponential growth. When the rate of cell division decreased, phosphorylase a activity also decreased while the glycogen levels increased. Glycogen synthase was almost entirely in b form during the entire culture period, i.e., in both the exponential and the stationary phases. In vitro incubation of the cellular extracts without NaF showed, however, that the enzyme could be partially converted to the a form by the endogenous phosphatases. The A0.5 values of the enzyme for glucose-6-phosphate (Glc-6-P) were of the same order of magnitude as the intracellular Glc-6-P concentrations which ranged from 2.2 to 5.4 mM (almost 10 times those reported in normal cells). Similar Glc-6-P values were obtained by two different extraction methods controlled by the intracellular ATP and ADP concentrations. The Km values for uridine-5'-diphosphoglucose were always 2 to 3 times lower than the intracellular uridine-5'-diphosphoglucose concentrations. These results suggest that: (a) in these tumor cells, glycogen is essentially synthesized by glycogen synthase b via an allosteric activation by intracellular Glc-6-P; (b) there is no obvious growth-related control of glycogen synthase activity; and (c) the activity of glycogen phosphorylase seems to be growth dependent with maximal phosphorylase a activities associated with the period of high division rate.

Adenosine Diphosphate↗
PubMed1983

Relationship between the secretor status and the expression of ABH blood group antigenic determinants in human intestinal brush-border membrane hydrolases.

At least six hydrolases of the human intestinal brush-border membrane bear ABH blood group antigenic determinants related to the erythrocyte phenotype: the intestinal glycoproteins of blood group A and B subjects express A or B determinants, respectively, while blood group O subjects express the H determinant identified with Ulex europaeus lectin I. These expressions are under the control of the secretor gene: ABH antigens were not detected in the hydrolases of non-secretor subjects.

ABO Blood-Group System↗
PubMed1983

Sucrase-isomaltase: a marker of foetal and malignant epithelial cells of the human colon.

The presence of sucrase-isomaltase (SI), a glycoprotein hydrolase normally restricted to the brush border membrane of the enterocytes of the small intestine, was investigated in tumours which developed in nude mice inoculated with six human colon carcinoma cell lines (HT-29, Caco-2, HRT-18, HCT-8R, SW-480, and CO-115). Foetal and normal adult human small intestines and colons were used as controls. SI was studied by (1) immunofluorescence with rabbit antibodies raised against purified human small intestine SI; (2) polyacrylamide gel electrophoresis and immunoblotting; and (3) determination of the enzyme activity. SI was antigenically present, and enzymatically active, in all the tumours derived from Caco-2 and HT-29 cells. The presence of the enzyme was associated with that of typical brush borders at transmission electron microscopy examination. SI was absent from the tumours developed with the other four cell lines, as well as from the normal adult colon mucosa. SI was also present and active in the colons of mid-gestation foetuses, ranging in ages between 20 and 28 weeks; it was absent from the colons of late-gestation foetuses. The presence of SI in tumours derived from two cell lines suggests that this enzyme is a marker, so far unsuspected, of certain human colon cancers, and that the differentiation pattern of these particular cancers closely resembles that of the foetal colon.

Animals↗
PubMed1983

Activity of glycogen metabolizing enzymes in glucose deprived HT 29 adenocarcinoma cell-line.

When deprived of glucose, the cultured HT 29 adenocarcinoma cells are able to mobilize their glycogen within 4 hours. Glycogen phosphorylase is strongly activated during the first hour of glucose starvation. Then, while the a/a + b ratio for phosphorylase is declining, glycogen synthase is partially converted into the a form; this conversion does occur although glycogen phosphorylase is far from being totally inactivated. After 4 hours, activity of both a and total forms of glycogen synthase decrease. Cell UDP-glucose and glucose-6-P levels are declining during the 24 hours period of glucose starvation. Cell ATP content decreases by only 50 percent over the same period of time.

Adenocarcinoma↗
PubMed1982

Variations of glycogen level and alpha-glucosidase activity in human malignant epithelial cell lines in culture.

1. Acid lysosomal and neutral alpha-glucosidase activities are measured during the culture of five human malignant epithelial cell lines, as a function of the growth-related glycogen accumulation. 2. Neutral alpha-glucosidase is found to be active mainly during the exponential phase of cell culture, which could be related to an enhancement of glycosylated compound synthesis. 3. The latent activity of the acid lysosomal alpha-glucosidase increases during the course of cell culture and especially when glycogen accumulates, suggesting that this enzyme could be involved in the control of the polysaccharide storage within the cell.

Cell Division↗
PubMed1980

A new bioassay of VIP: results in watery diarrhoea syndrome.

Cyclic AMP accumulation in human colon adenocarcinoma cells in culture (HT-29) is known to be particularly sensitive to the stimulating action of vasoactive intestinal peptide (VIP). This property was exploited as a means of investigating the possible role of VIP as a humoral mediator in the watery diarrhoea syndrome. Our results showed that plasma from two patients with watery diarrhoea syndrome associated with ganglioneuroblastoma and pheochromocytoma strongly stimulated cyclic AMP accumulation in HT-29 cells, whereas plasma from normal subjects and patients with other diarrhoeal disorders had no effect. The stimulation induced by serial dilutions of plasma from patients paralleled the VIP-induced response. Preincubation of these plasmas with specific anti-VIP antibody prevented their stimulatory effects. Plasma sampled after the arrest of diarrhoea (spontaneous or after surgical resection of tumours) elicited AMP rise in HT-29 cells. Tumour extract stimulated cyclic AMP accumulation in HT-29 cells with a dose-response curve which was superimposable on the one obtained with standard VIP. The results lend support to the hypothesis that VIP is a humoral mediator in WDS and suggest that the diarrhoea is mediated through a VIP-induced accumulation of cyclic AMP in intestinal epithelial cells.

Adrenal Gland Neoplasms↗
PubMed1980

Vasoactive intestinal peptide control of cyclic adenosine 3':5'-monophosphate levels in seven human colorectal adenocarcinoma cell lines in culture.

This study was undertaken to assess the role of vasoactive intestinal peptide (VIP) in the control of cyclic adenosine 3':5'-monophosphate production in colonic tumor cells. Seven human colorectal adenocarcinoma cell lines in culture were investigated (HT-29, HRT-18, SW-480, Caco-2, CO-115, CO-125, and HCT-8R). These cell-lines had a cyclic adenosine 3':5'-monophosphate production system which was very sensitive to VIP but less so to prostaglandin E1 and/or isoproterenol. Nonintestinal human malignant epithelial cells, such as HeLa (cervix) and Caki-1 and Caki-2 (kidney), by contrast, did not respond to VIP. The dose-response relationships of malignant colorectal cells were compared to those obtained with epithelial cells of normal human colon and showed that: (a) maximal responses were observed with 0.1 micro M VIP in both malignant and normal cells; (b) half-maximal responses were elicited by VIP concentrations in the 0.3 to 2 nM range in malignant cells (1.2 nM in normal cells), thus indicating the high apparent affinity of the cells to VIP; and (c) the magnitudes of the responses (stimulated:basal ratios) were highly variable in malignant cells, ranging from 225 in HT-29 cells to 3.5 in Caco-2 cells, but were more constant, in the order of 25, in normal cells. Secretin, a VIP agonist in intestinal tissue, stimulated cyclic adenosine 3':5'-monophosphate accumulation in all colorectal cells, but with a 1000- to 5000-fold lower potency than did VIP. These results show that the VIP-sensitive adenylate cyclase system operates in malignant as well as in normal colon epithelial cells.

Adenocarcinoma↗
PubMed1980

Growth-related glycogen levels of human intestine carcinoma cell lines grown in vitro and in vivo in nude mice.

The relationship known to exist in vitro between glycogen accumulation and the growth of malignant human intestine epithelial cells was investigated in vivo. The glycogen concentration of 7 human intestine carcinoma cell lines (Caco-2, HT-29, HRT-18, HCT-8R, CO-115, SW-480, and HuTu 80) was measured during cell growth for the in vitro series and during the course of tumor growth for the in vivo series. The glycogen stores were compared for these cells in vitro and after their injection in noninbred Swiss athymic nude mice. The tumors and cultured cells were ranked identically on the basis of glycogen level (Caco-2 > HRT-18 > HT-29 > HCT-8R > CO-115 > SW-480 > HuTu 80). Values for the tumors ranged from 128.8 +/- 10.8 micrograms glycogen/mg protein for Caco-2 tumors down to 2.9 +/- 0.9 micrograms for HuTu 80 tumors; similar values were found for the exponentially growing corresponding cultured cells. The tumor glycogen concentration was independent of the host's nutritional state: Glycogen concentration differed from one type of tumor to another despite its constant level in the liver; fasting did not cause tumor glycogenolysis. By the two experimental approaches, results varied during the growth phases: Stationary phase glycogen concentration increased threefold to fourfold for all cultured cell lines; tumor glycogen concentration, by contrast, was stable throughout the growth period. An inverse relationship was nonetheless found between the rate of tumor growth and tumor glycogen concentration; the highest glycogen content was associated with the slowest growing tumors, and conversely. Apparently, elevated glycogen concentration is regularly associated with decreased cell division rates in vitro and in vivo.

Adenocarcinoma↗
PubMed1979

Presence and cell growth-related variations of glycogen in human colorectal adenocarcinoma cell lines in culture.

The presence and kinetics of intracellular glycogen levels were studied, in relationship to cell growth, in asynchronous and in synchronized cultures of four human colorectal adenocarcinoma cell lines (HT-29, HRT-18, SW-480, and Caco-2). The results show that a specific pattern of glycogen accumulation occurs during the process of cell growth of the studied cell lines. The kinetics of glycogen accumulation in asynchronous cultures were similar from one cell line to another and were characterized by a low amount in the exponential phase of growth, followed by a 3- to 4-fold increase in the stationary phase. The quantities found in either phase were specific for each cell line. The maximum values found in Caco-2, HRT-18, HT-29, and SW-480 cells were, respectively, 258.5 +/- 6.9 (S.D.), 88.9 +/- 2.6, 87.5 +/- 3, and 17.5 +/- 1.8 microgram of glycogen per mg of proteins. The kinetics of glycogen accumulation during the cell cycle was also studied in synchronized cultures of HT-29 and HRT-18 cell lines. Both cell lines exhibited a common pattern of low glycogen quantities during S, G2, and M followed by an increase beginning with G1 and peaking (2.5 to 3 times the initial values) in the middle of this phase. This was followed by a symmetrical decrease in the second half of G1.

Adenocarcinoma↗
PubMed1978

[Phenotypic expression of colon polymorphic antigens (WZ) in human colon adenocarcinomas].

Human colon adenocarcinomas from 52 patients were investigated for the presence of the colon polymorphic antigens WZ. The patients were typed for their WZ phenotype, using the immunofluorescence method on non tumoral colon mucosa sections: 27 patients were found W+ Z+, 18 W- Z+, and 7 W- Z-. The tumors were tested for the presence of the WZ phenotypes, using the immunofluorescence method and a radio-immunoassay. The WZ phenotypes were not expressed in the non secreting tumors, whatever the patient's phenotype. They were expressed in the secreting tumors and had the same phenotype as found in the corresponding normal mucosa. The WZ phenotypes were present in human developed into "nude" Mice inoculated either with differentiated colon carcinomas, or with a human colon carcinoma cell line (HT-29).

Adenocarcinoma↗
PubMed1978

Vasoactive intestinal peptide: a potent stimulator of adenosine 3':5'-cyclic monophosphate accumulation in gut carcinoma cell lines in culture.

Vasoactive intestinal peptide (VIP) is a potent and efficient stimulator of adenosine 3':5'-cyclic monophosphate (cAMP) accumulation in a human colon carcinoma cell line, HT 29. cAMP accumulation is sensitive to a concentration of VIP as low as 3x10(-12) M. Maximum VIP-induced cAMP levels were observed with 10(-9) M VIP and are about 200 times above the basal levels. Half-maximum cAMP production was obtained at 3x10(-10) M VIP. (125)I-Labeled VIP was found to bind to HT 29 cells; this binding was competitively inhibited by concentrations of unlabeled VIP between 10(-10) and 10(-7) M. Half-maximum inhibition of binding was observed with 2x10(-9) M VIP. Secretin also stimulated cAMP accumulation in HT 29 cells, but its effectiveness was 1/1000 that of VIP. The other peptides tested at 10(-7) M, such as insulin, glucagon, bovine pancreatic polypeptide, somatostatin, octapeptide of cholecystokinin, neurotensin, and substance P, did not stimulate cAMP accumulation. Prostaglandin E(1) and catecholamines stimulated cAMP production but were 1/2.3 and 1/5.5 as efficient as VIP, respectively. Another malignant cell line from the gut, the human rectal tumor cell line HRT 18, is also sensitive to VIP. In HRT 18 cells, VIP stimulated cAMP accumulation with a maximal effect at 10(-8) M; half-maximum stimulation was observed at about 10(-9) M. These results demonstrate the presence of VIP receptors in two malignant human intestinal cell lines (HT 29 and HRT 18) in culture and provide a model for studying the action of VIP on cell proliferation.

Adenocarcinoma↗